Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Phase 2

Withdrawn

Conditions: Soft Tissue Sarcoma Adult
Advanced Cancer

Interventions: Drug: Apatinib

First Posted Date: 2017-04-07

Last Posted Date: 2020-05-19

Lead Sponsor: Peking University People's Hospital

Registration Number: NCT03104335

Locations: 🇨🇳
Peking University International Hospital, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Phase 2

Completed

Conditions: Advanced Primary Liver Cancer
Advanced Biliary Tract Carcinoma

Interventions: Biological: SHR-1210
Drug: FOLFOX4
Drug: Apatinib
Drug: GEMOX

First Posted Date: 2017-03-28

Last Posted Date: 2023-02-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 157

Registration Number: NCT03092895

Locations: 🇨🇳
Cancer Hospital of Henan province, Zhengzhou, Henan, China
🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

and more 4 locations

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Phase 2

Conditions: Breast Cancer Metastatic

Interventions: Drug: Apatinib

First Posted Date: 2017-03-22

Last Posted Date: 2018-01-17

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 120

Registration Number: NCT03086785

Locations: 🇨🇳
Fourth Hospital of Hebei Medical University, ShiJiazhuang, Hebei, China

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: SHR-1210
Drug: Apatinib

First Posted Date: 2017-03-17

Last Posted Date: 2023-02-03

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 210

Registration Number: NCT03083041

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Phase 1

Completed

Conditions: Ovarian Cancer
Triple Negative Breast Cancer

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2017-03-09

Last Posted Date: 2022-07-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 98

Registration Number: NCT03075462

Locations: 🇨🇳
Beijing Cancer Hosptial, Beijing, Beijing, China

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Phase 1

Conditions: Metastatic Gastric Adenocarcinoma

Interventions: Drug: Apatinib
Drug: Docetaxel

First Posted Date: 2017-03-06

Last Posted Date: 2017-03-06

Lead Sponsor: Sir Run Run Shaw Hospital

Target Recruit Count: 12

Registration Number: NCT03071042

Locations: 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China

A Phase II Study of Apatinib in STS Patients

Phase 2

Conditions: Soft Tissue Sarcoma

Interventions: Drug: apatinib

First Posted Date: 2017-02-27

Last Posted Date: 2017-02-27

Lead Sponsor: Shanghai Jiao Tong University Affiliated Sixth People's Hospital

Target Recruit Count: 53

Registration Number: NCT03064243

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Apatinib

First Posted Date: 2017-02-08

Last Posted Date: 2017-02-08

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT03046979

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Phase 3

Completed

Conditions: Gastric Cancer
Gastric Adenocarcinoma

Interventions: Drug: Placebo
Drug: Rivoceranib

First Posted Date: 2017-02-03

Last Posted Date: 2022-07-08

Lead Sponsor: Elevar Therapeutics

Target Recruit Count: 460

Registration Number: NCT03042611

Locations: 🇮🇹
Ospedali Riuniti di Ancona - SOD Clinica Oncologica, Torrette, Italy
🇮🇹
U.O Di Oncologia Ospedale Degli Infermi, Faenza, Italy
🇰🇷
Chungbuk National University Hospital, Chungbuk, Korea, Republic of

and more 92 locations

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Phase 2

Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Interventions: Drug: Apatinib
Drug: Irinotecan

First Posted Date: 2017-01-25

Last Posted Date: 2017-01-25

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 74

Registration Number: NCT03030937

Locations: 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy